Financial instruments - Collaboration and License Agreement (Details) $ in Thousands |
6 Months Ended | 12 Months Ended | 43 Months Ended | |||
|---|---|---|---|---|---|---|
|
Dec. 31, 2015
customer
|
Dec. 31, 2017
USD ($)
customer
|
Dec. 31, 2016
USD ($)
customer
|
Jun. 30, 2015
customer
|
Dec. 31, 2017
USD ($)
|
Sep. 30, 2017
USD ($)
|
|
| Collaboration and License Agreement | ||||||
| Number of customers | customer | 1 | 1 | 1 | 1 | ||
| GlaxoSmithKline Intellectual Property Development Ltd | Collaboration and License Agreement | ||||||
| Collaboration and License Agreement | ||||||
| Trade receivables | $ 1,500 | $ 200 | ||||
| Impairment losses | $ 0 | |||||
| Amounts past due | $ 0 | $ 0 | ||||
| X | ||||||||||
- Definition Number of customers. No definition available.
|
| X | ||||||||||
- Definition Amounts past due. No definition available.
|
| X | ||||||||||
- Definition Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|